Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine

被引：417

作者：

Fais, Stefano ^{[1
]}

O'Driscoll, Lorraine ^{[2
,3
]}

Borras, Francesc E. ^{[4
,5
]}

Buzas, Edit ^{[6
]}

Camussi, Giovanni ^{[7
]}

Cappello, Francesco ^{[8
,9
]}

Carvalho, Joana ^{[10
,11
]}

da Silva, Anabela Cordeiro ^{[10
,13
,14
]}

Del Portillo, Hernando ^{[15
,16
]}

El Andaloussi, Samir ^{[17
,18
]}

Trcek, Tanja Ficko ^{[19
]}

Furlan, Roberto ^{[20
]}

Hendrix, An ^{[21
]}

Gursel, Ihsan ^{[22
]}

Kralj-Iglic, Veronika ^{[23
]}

Kaeffer, Bertrand ^{[24
,25
]}

Kosanovic, Maja ^{[26
]}

Lekka, Marilena E. ^{[27
]}

Lipps, Georg ^{[28
]}

Logozzi, Mariantonia ^{[1
]}

Marcilla, Antonio ^{[29
,30
]}

Sammar, Marei ^{[31
]}

Llorente, Alicia ^{[32
]}

Nazarenko, Irina ^{[33
,34
]}

Oliveira, Carla ^{[10
,11
,12
]}

Pocsfalvi, Gabriella ^{[35
]}

Rajendran, Lawrence ^{[36
]}

Raposo, Graca ^{[37
,38
]}

Rohde, Eva ^{[39
,40
]}

Siljander, Pia ^{[41
,42
]}

van Niel, Guillaume ^{[38
]}

Vasconcelos, M. Helena ^{[10
,11
]}

Yanez-Mo, Maria ^{[43
]}

Yliperttula, Marjo L. ^{[42
]}

Zarovni, Natasa ^{[44
]}

Zavec, Apolonija Bedina ^{[45
]}

Giebel, Bernd ^{[46
]}

机构：

[1] Natl Inst Hlth ISS, Antitumor Drugs Sect, Dept Therapeut Res & Med Evaluat, I-00161 Rome, Italy

[2] Trinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Dublin 2, Ireland

[3] Trinity Coll Dublin, Trinity Biomed Sci Inst, Dublin 2, Ireland

[4] Germans Trias & Pujol Univ Hosp, Germans Trias & Pujol Res Inst IGTP, IVECAT Grp, Campus Can Ruti, Badalona 08916, Spain

[5] Germans Trias & Pujol Univ Hosp, Serv Nephrol, Campus Can Ruti, Badalona 08916, Spain

[6] Semmelweis Univ, Dept Genet Cell & Immunobiol, H-1085 Budapest, Hungary

[7] Univ Turin, Dept Med Sci, Ctr Mol Biotechnol, Turin 8, Italy

[8] Univ Palermo, Dept Expt Biomed & Clin Neurosci, Human Anat Sect, I-90133 Palermo, Italy

[9] Euromediterranean Inst Sci & Technol, I-90133 Palermo, Italy

[10] Univ Porto IPATIMUP, Inst Invest & Inovacao Saude i3S, P-4200135 Oporto, Portugal

[11] Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, P-4200135 Oporto, Portugal

[12] Univ Porto, Dept Pathol & Oncol, Fac Med, P-4200319 Oporto, Portugal

[13] Univ Porto, Dept Biol Sci, Fac Pharm, P-4050313 Oporto, Portugal

[14] Inst Mol & Cell Biol, Rua Campo Alegre, P-4150180 Oporto, Portugal

[15] Univ Barcelona, Hosp Clin, Barcelona Ctr Int Hlth Res CRESIB, ICREA, E-08036 Barcelona, Spain

[16] Inst Invest Germans Trias & Pujol IGTP, ICREA, Badalona 08916, Spain

[17] Karolinska Inst, Dept Lab Med, S-17177 Stockholm, Sweden

[18] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3QX, England

[19] Lek Pharmaceut Dd, Sandoz Biopharmaceut, Menges, Slovenia

[20] Ist Sci San Raffaele, Inst Expt Neurol, Div Neurosci, I-20132 Milan, Italy

[21] Ghent Univ Hosp, Dept Radiat Oncol & Expt Canc Res, Lab Expt Canc Res, B-9000 Ghent, Belgium

[22] Bilkent Univ, Fac Sci, Mol Biol & Genet Dept, THORLAB Therapeut Oligonucleotide Res Lab, TR-06800 Bilkent, Turkey

[23] Univ Ljubljana, Lab Clin Biophys, Fac Hlth Sci, Ljubljana 1000, Slovenia

[24] INRA, UMR 1280, F-44300 Nantes, France

[25] Univ Nantes, F-44300 Nantes, France

[26] Univ Belgrade, Inst Applicat Nucl Energy, Dept Immunochem & Glycobiol, INEP, Belgrade 11000, Serbia

[27] Univ Ioannina, Dept Chem, GR-45110 Ioannina, Greece

[28] Univ Appl Sci & Arts Northwestern Switzerland, Grundenstr 40, CH-4132 Muttenz, Switzerland

[29] Univ Valencia, Fac Farm, Dept Biol Celular & Parasitol, E-46010 Valencia, Spain

[30] Univ Valencia, Joint Res Unit Endocrinol Nutr & Clin Dietet, Hlth Res Inst La Fe, Valencia 46010, Spain

[31] ORT Braude Coll, Prof Ephraim Katzir Dept Biotechnol Engn, IL-2161002 Karmiel, Israel

[32] Norwegian Radium Hosp, Oslo Univ Hosp, Inst Canc Res, Dept Mol Cell Biol, N-0379 Oslo, Norway

[33] Univ Freiburg, Med Ctr, Inst Environm Hlth Sci, Hugstetter Str 55, D-79106 Freiburg, Germany

[34] Univ Freiburg, Med Ctr, Hosp Infect Control, Hugstetter Str 55, D-79106 Freiburg, Germany

[35] Natl Res Council Italy, Inst Biosci & BioResources, Mass Spectrometry & Prote, I-80131 Naples, Italy

[36] Univ Zurich, Syst & Cell Biol Neurodegenerat, CH-8006 Zurich, Switzerland

[37] PSL Res Univ, Ctr Rech, Inst Curie, UMR144, 26 Rue ULM, F-75231 Paris, France

[38] Ctr Natl Rech Sci, UMR144, F-75231 Paris, France

[39] Paracelsus Med Univ, Spinal Cord Injury & Tissue Regenerat Ctr Salzbur, A-5020 Salzburg, Austria

[40] Salzburger Landeskliniken GesmbH SALK, Univ Hosp, Dept Blood Grp Serol & Transfus Med, A-5020 Salzburg, Austria

[41] Univ Helsinki, Dept Biosci, Div Biochem & Biotechnol, SF-00100 Helsinki, Finland

[42] Univ Helsinki, Fac Pharm, Div Pharmaceut Biosci, SF-00100 Helsinki, Finland

[43] UAM, Dept Biol Mol CBM SO, IIS IP, Unidad Invest,Hosp Sta Cristina, Madrid 28009, Spain

[44] Exos Siena SpA, I-53100 Siena, Italy

[45] Natl Inst Chem, Lab Mol Biol & Nanobiotechnol, Ljubljana 1000, Slovenia

[46] Univ Duisburg Essen, Univ Hosp Essen, Inst Transfus Med, D-45147 Essen, Germany

来源：

ACS NANO | 2016年 / 10卷 / 04期

关键词：

CELL-DERIVED EXOSOMES; BRONCHOALVEOLAR LAVAGE FLUID; MESENCHYMAL STROMAL CELLS; PROSTATE-CANCER MORTALITY; DRUG-DELIVERY; SIRNA DELIVERY; MYELOID MICROVESICLES; CIRCULATING EXOSOMES; SAMPLE COLLECTION; URINARY EXOSOMES;

D O I：

10.1021/acsnano.5b08015

中图分类号：

O6 [化学];

学科分类号：

070301 [无机化学];

摘要：

Recent research has demonstrated that all body fluids assessed contain substantial amounts of vesicles that range in size from 30 to 1000 nm and that are surrounded by phospholipid membranes containing different membrane microdomains such as lipid rafts and caveolae. The most prominent representatives of these so-called extracellular vesicles (EVs) are nanosized exosomes (70-150 nm), which are derivatives of the endosomal system, and microvesicles (100-1000 nm), which are produced by outward budding of the plasma membrane. Nanosized EVs are released by almost all cell types and mediate targeted intercellular communication under physiological and pathophysiological conditions. Containing cell-type specific signatures, EVs have been proposed as biomarkers in a variety of diseases. Furthermore, according to their physical functions, EVs of selected cell types have been used as therapeutic agents in immune therapy, vaccination trials, regenerative medicine, and drug delivery. Undoubtedly, the rapidly emerging field of basic and applied EV research will significantly influence the biomedicinal landscape in the future. In this Perspective, we, a network of European scientists from clinical, academic, and industry settings collaborating through the H2020 European Cooperation in Science and Technology (COST) program European Network on Microvesicles and.Exosomes in Health and Disease (ME-HAD), demonstrate the high potential of nanosized EVs for both diagnostic and therapeutic (i.e., theranostic) areas of nanomedicine.

引用

页码：3886 / 3899

页数：14

共 152 条

[1]

Exosomes with major histocompatibility complex class II and co-stimulatory molecules are present in human BAL fluid [J].